{"id":"du-176b-edoxaban","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL2105682","moleculeType":"Small molecule","molecularWeight":"720.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Edoxaban selectively inhibits Factor Xa, a serine protease critical in the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa activity, it prevents the generation of thrombin and subsequent fibrin clot formation, reducing thrombotic events. As an oral anticoagulant, it provides systemic anticoagulation without requiring monitoring or dose adjustment in most patients.","oneSentence":"Edoxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:10.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Deep vein thrombosis and pulmonary embolism treatment and prevention"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT03488420","phase":"","title":"Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE","status":"COMPLETED","sponsor":"Montreal Heart Institute","startDate":"2019-04-30","conditions":"Atrial Fibrillation and Flutter, Valvular Heart Disease","enrollment":136},{"nctId":"NCT03395639","phase":"PHASE3","title":"Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-05-15","conditions":"Cardiac Disease","enrollment":168},{"nctId":"NCT02801669","phase":"PHASE3","title":"Study of DU-176b Aged 80 Years or Older","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-08-05","conditions":"Atrial Fibrillation","enrollment":984},{"nctId":"NCT02072434","phase":"PHASE3","title":"Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-03-25","conditions":"Atrial Fibrillation","enrollment":2199},{"nctId":"NCT02073682","phase":"PHASE3","title":"Cancer Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-07-16","conditions":"Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)","enrollment":1046},{"nctId":"NCT01181102","phase":"PHASE3","title":"A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2009-03","conditions":"Venous Thromboembolism","enrollment":716},{"nctId":"NCT00781391","phase":"PHASE3","title":"Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-11","conditions":"Stroke, Atrial Fibrillation, Embolism","enrollment":21105},{"nctId":"NCT01857583","phase":"PHASE3","title":"Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2012-03","conditions":"Venous Thromboembolism","enrollment":80},{"nctId":"NCT01181141","phase":"PHASE3","title":"Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2008-10","conditions":"Venous Thromboembolism","enrollment":92},{"nctId":"NCT01181167","phase":"PHASE3","title":"A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2009-05","conditions":"Prevention, Venous Thromboembolism","enrollment":610},{"nctId":"NCT01857622","phase":"PHASE3","title":"Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2011-11","conditions":"Non-valvular Atrial Fibrillation","enrollment":93},{"nctId":"NCT00986154","phase":"PHASE3","title":"Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-10","conditions":"Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)","enrollment":8292},{"nctId":"NCT01662908","phase":"PHASE2","title":"A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-08","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":85},{"nctId":"NCT00107900","phase":"PHASE2","title":"Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2005-01","conditions":"Arthroplasty, Replacement, Hip, Thrombosis","enrollment":606},{"nctId":"NCT00504556","phase":"PHASE2","title":"A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-06","conditions":"Atrial Fibrillation, Thromboembolism","enrollment":1146},{"nctId":"NCT00806624","phase":"PHASE2","title":"DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2007-10","conditions":"Atrial Fibrillation, Stroke","enrollment":234},{"nctId":"NCT01203072","phase":"PHASE2","title":"A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2006-07","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Total Knee Arthroplasty","enrollment":523},{"nctId":"NCT00829933","phase":"PHASE2","title":"Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2007-03","conditions":"Atrial Fibrillation","enrollment":536},{"nctId":"NCT01203098","phase":"PHASE2","title":"A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2008-07","conditions":"Venous Thromboembolism, Thromboembolism, Thrombosis","enrollment":264},{"nctId":"NCT02448901","phase":"","title":"Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography","status":"UNKNOWN","sponsor":"LifeBridge Health","startDate":"2015-04","conditions":"Heart Failure","enrollment":40},{"nctId":"NCT02221102","phase":"PHASE2, PHASE3","title":"Edoxaban for TIA and Acute Minor Stroke","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2013-12","conditions":"Ischemia, Stroke, Cerebral Infarction","enrollment":3700}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2599,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DU-176b (edoxaban)","genericName":"DU-176b (edoxaban)","companyName":"Daiichi Sankyo Co., Ltd.","companyId":"daiichi-sankyo-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Edoxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis and pulmonary embolism treatment and prevention, Acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}